IPCA Laboratories Share Price Target 2027: Base and Bull Targets Built on FY26 Earnings
- October 9, 2026
- Posted by: Kunal Singla
- Category: Market
IPCA Laboratories share price Rs 1,905.00 (9 October 2026). Base target Rs 2,315, bull Rs 2,773, downside risk Rs 1,543. PE 35.59. 52W range Rs 1,251.60 to Rs 2,038.00.
Quick Answer
The IPCA Laboratories share price target for 2027 is Rs 2,315, about 21.5% above the current price of Rs 1,905.00. The bull case is Rs 2,773, and the downside risk level, which is not a target, is Rs 1,543. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 44.4%, with the stock holding its PE of 35.59. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing an IPCA Laboratories target price for 2027 should start with where the stock sits today. At Rs 1,905.00 on 9 October 2026, it is 6.5% below its 52-week high of Rs 2,038.00 and 52.2% above its 52-week low of Rs 1,251.60. That range spans 63% from low to high, so the entry point matters as much as the IPCA Laboratories price forecast itself.
This article builds the IPCA Laboratories share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario shows its assumptions, so you can see exactly how the Rs 2,315 base case and the Rs 2,773 bull case were reached, along with a downside risk level of Rs 1,543.
Click Here – Get Free Investment Predictions
IPCA Laboratories Stock Analysis: Company Overview and Key Stats
IPCA Laboratories (NSE: IPCALAB) has a market capitalisation of Rs 48,941 crore. In FY26 it reported revenue of Rs 9,821 crore and net profit of Rs 1,191 crore. The table collects the figures the IPCA Laboratories share price target is built on.
| Metric | Value |
|---|---|
| Company | IPCA Laboratories |
| NSE Ticker | IPCALAB |
| CMP (9 October 2026) | Rs 1,905.00 |
| 52-Week High | Rs 2,038.00 |
| 52-Week Low | Rs 1,251.60 |
| Market Cap | Rs 48,941 crore |
| PE Ratio (TTM) | 35.59 |
| Industry PE | 37.59 |
| Price to Book | 6.07 |
| Return on Equity | 14.15% |
| Debt to Equity | 0.10 |
| EPS (TTM) | Rs 54.20 |
| Dividend Yield | 0.31% |
| 12-Month Base Target | Rs 2,315 |
| Bull Case | Rs 2,773 |
| Downside Risk Level (not a target) | Rs 1,543 |
Why Is IPCA Laboratories Share Price Target Set at Rs 2,315 for 2027?
The base-case IPCA Laboratories stock target of Rs 2,315 applies a PE multiple of 35.59 to a forward EPS estimate of Rs 65.04. That EPS assumes 20.0% yearly growth, the pace from FY24 to FY26, and puts the target 21.5% above the current price. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the IPCA Laboratories Target Price: Five Years of Results
IPCA Laboratories grew revenue from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew more slowly, from Rs 910.95 crore to Rs 1,191 crore (6.9% a year), which points to margin pressure alongside the sales growth.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 5,896.36 | 910.95 | 34.85 | 8.00 |
| FY23 | 6,369.94 | 491.93 | 18.58 | 4.00 |
| FY24 | 7,829.81 | 529.21 | 21.57 | 4.00 |
| FY25 | 9,032.39 | 787.53 | 29.08 | 4.00 |
| FY26 | 9,820.78 | 1,191.37 | 44.98 | 0.00 |
FY26 revenue growth was 8.7%, slower than the four-year average of 13.6%, and net profit moved up 51.3%. EPS rose from Rs 21.57 in FY24 to Rs 44.98 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
IPCA Laboratories converted 12.1% of FY26 revenue into net profit, against 8.7% in FY25, within a five-year range of 6.8% to 15.4%. EBITDA margin was 21.0% in FY26 versus 17.9% in FY25.
In the June 2026 quarter, revenue was Rs 2,813 crore, up 20.2% from the same quarter a year earlier, while net profit of Rs 422.81 crore was up 80.4%. EBITDA came in at Rs 694.77 crore, up 54.7% year on year. The next quarterly result is the first test of whether the earnings assumption holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.10, and shareholders’ equity grew from Rs 5,569 crore in FY22 to Rs 9,524 crore in FY26. Operating cash flow in FY26 was Rs 1,142 crore against capital expenditure of Rs 655.95 crore, leaving free cash flow of Rs 486.02 crore, or 1.0% of the current market capitalisation. In FY25 free cash flow was Rs 545.80 crore.
Valuation Check for the IPCA Laboratories Stock Target: PE, Price to Book and ROE
At a PE of 35.59 against an industry PE of 37.59, IPCA Laboratories trades in line with its industry. Price to book is 6.07 on a book value of Rs 317.84 per share, and return on equity is 14.15%. A PE of 35.59 equals an earnings yield of 2.8%, and the FY26 dividend of Rs 0.00 per share gives a yield of 0.31%.
Shareholding Pattern and Institutional Holding
Promoters held 44.72% of IPCA Laboratories in June 2026, and promoter holding has stayed near 44.72% since June 2025. Foreign institutional investors (FII) held 10.73% and domestic institutions (DII) held 37.37%, which puts total institutional holding at 48.10%. FII holding has stayed near 10.73% since June 2025. Public shareholders own the remaining 7.18%. A meaningful institutional holding adds a layer of research coverage and trading depth.
IPCA Laboratories Share Price Targets for the Short Term and 12 Months
Short Term IPCA Laboratories Stock Target Levels: Technical Setup
At Rs 1,905.00 on 9 October 2026, IPCA Laboratories trades above its 50-day simple moving average of Rs 1,899.27 and above its 200-day exponential moving average of Rs 1,695.46. The 14-day RSI reads 30.7, which is neutral territory, and the MACD line sits below its signal line. The nearest resistance level is Rs 2,038.00 (52-week high) and the nearest support is Rs 1,899.27 (50-day simple moving average). A sustained move above Rs 2,038.00 would improve the short-term setup, while a close below Rs 1,899.27 would shift attention to the next support.
12 Month IPCA Laboratories Target Price for 2027
The 12-month target for IPCA Laboratories is Rs 2,315: forward EPS of Rs 65.04 at a PE of 35.59. That is 21.5% above Rs 1,905.00. It would also push the stock above its 52-week high of Rs 2,038.00.
How EPS Growth and PE Multiple Change the IPCA Laboratories Target Price
| EPS Growth | PE 28.47 | PE 35.59 | PE 40.93 |
|---|---|---|---|
| 0.0% (EPS Rs 54.20) | Rs 1,543 | Rs 1,929 | Rs 2,218 |
| 20.0% (EPS Rs 65.04) | Rs 1,852 | Rs 2,315 | Rs 2,662 |
| 25.0% (EPS Rs 67.75) | Rs 1,929 | Rs 2,411 | Rs 2,773 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the IPCA Laboratories price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for IPCA Laboratories Stock Target in 2027
Bull Case Rs 2,773
The bull case IPCA Laboratories price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 67.75, and a PE multiple that rises 15% to 40.93. That gives Rs 2,773, 45.6% above the current price and above the 52-week high of Rs 2,038.00, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 1,543
The downside risk level is not a target. It assumes EPS stays flat at Rs 54.20 and the PE falls 20% to 28.47. That gives Rs 1,543, 19.0% below the current price and above the 52-week low of Rs 1,251.60.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 25.0% | 40.93 | Rs 2,773 | +45.6% |
| Base Case | 20.0% | 35.59 | Rs 2,315 | +21.5% |
| Downside Risk | 0.0% | 28.47 | Rs 1,543 | -19.0% |
Key Risks to the IPCA Laboratories Target Price for 2027
Growth Slowdown Risk for the IPCA Laboratories Price Target
Revenue in the June 2026 quarter was up 20.2% year on year, and FY26 revenue growth was 8.7%. If growth slows from here, the EPS estimate behind the IPCA Laboratories stock target will need revising.
Liquidity and Size Risk
IPCA Laboratories has a market capitalisation of Rs 48,941 crore. Institutional holding is 48.10%, and promoters hold 44.72%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.
Valuation and Margin Risk
Net margin was 12.1% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 35.59 versus an industry PE of 37.59, a de-rating toward the downside-risk PE of 28.47 would cut the price even if earnings hold.
Market and Technical Risk
The stock trades 6.5% below its 52-week high, with an RSI of 30.7 and a MACD reading below its signal line. Broader market weakness can override company fundamentals in the short term.
How to Invest in IPCA Laboratories
Start with the live price and volume. Any IPCA Laboratories share price target is only as current as the data behind it, and the data here is as of 9 October 2026, so refresh the Rs 1,905.00 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check IPCA Laboratories’ PE, ROE, debt and shareholding in one place.
Check IPCA Laboratories fundamentals on the Univest Screener
Then compare the three IPCA Laboratories target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track IPCA Laboratories live price and get daily stock recommendations.
Conclusion
The IPCA Laboratories share price target for 2027 is Rs 2,315 in the base case, with Rs 2,773 as the bull case. The support for that view is arithmetic you can check: EPS grew 44.4% a year over FY24 to FY26, and the stock trades at a PE of 35.59. The risks are equally concrete, including a stock that sits 6.5% below its 52-week high and a downside scenario that cuts the price 19% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on IPCA Laboratories Share Price Target 2027
What is the IPCA Laboratories share price target for 2027?
Ans. The base-case IPCA Laboratories share price target for 2027 is Rs 2,315, with Rs 2,773 as the bull case. The downside risk level, which is not a target, is Rs 1,543. These are model estimates from reported earnings and the current PE, not guaranteed outcomes.
What is the IPCA Laboratories share price today?
Ans. As of 9 October 2026, 3:29 PM IST, IPCA Laboratories trades at Rs 1,905.00, down 1.72% on the day. The 52-week range is Rs 1,251.60 to Rs 2,038.00.
Is IPCA Laboratories a buy or sell at the current price?
Ans. The data is mixed rather than one-sided: EPS has grown 44.4% a year over FY24 to FY26, but the stock is 6.5% below its 52-week high. Whether IPCA Laboratories fits your portfolio depends on your time horizon and risk appetite, so consult a SEBI-registered advisor before investing. This article is not investment advice.
What are the bull case target and downside risk level for IPCA Laboratories shares?
Ans. The bull case target is Rs 2,773, which assumes 25.0% EPS growth and a PE of 40.93. The downside risk level is Rs 1,543, which assumes flat EPS and a PE of 28.47. It marks a risk, not a target.
What are the main risks to the IPCA Laboratories price target?
Ans. The main risks are slower revenue growth, a small market capitalisation of Rs 48,941 crore, a PE de-rating and short-term weakness in the broader market. Each is covered in the risk section above.
What is the PE ratio of IPCA Laboratories and how does it compare with the industry?
Ans. The PE ratio of IPCA Laboratories is 35.59 against an industry PE of 37.59. Price to book is 6.07 and return on equity is 14.15%. The base case in the IPCA Laboratories price target holds this PE constant.
Who owns IPCA Laboratories, and what is the promoter holding?
Ans. Promoters held 44.72% of IPCA Laboratories in June 2026. FII held 10.73%, DII held 37.37% and the public held 7.18%.
What were IPCA Laboratories’ latest quarterly results?
Ans. In the June 2026 quarter, IPCA Laboratories reported revenue of Rs 2,813 crore (up 20.2% year on year) and net profit of Rs 422.81 crore (up 80.4%).
